News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–15
Matches
15
Sources here
4
Companies here
1
Search results Stored financial headlines

Active search

15 matching headlines

Ticker or company: PMCBMain company stories
Clear
Latest

TradingKey Analyst action

PharmaCyte Biotech Inc (PMCB) Stock News Today

This article provides current stock information for PharmaCyte Biotech Inc (PMCB), including its latest stock price, daily change, market cap, and links to financial data, analyst ratings, and news. As of the report, PMCB closed at $0.553 with a 1.37% increase, and indicated that more news about the company is expected soon. The platform "TradingKey" serves as the …

Main company 🇺🇸 United States
Read at TradingKey
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
TradingKey Earnings Main company 🇺🇸 United States

PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PharmaCyte Biotech Inc (PMCB), detailing future EPS and revenue growth estimates. It includes a snapshot of the company's current stock price, market capitalization, and various financial metrics. The article also lists peer comparisons and indicates that the …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of PharmaCyte Biotech Inc (PMCB), detailing its current price momentum score, support and resistance levels, and indicator and moving average assessments. It highlights that PMCB's stock price is currently trading between a resistance level of 0.71 and a …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Earnings Main company 🇺🇸 United States

PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of PharmaCyte Biotech Inc (PMCB), noting its current valuation score of 8.50, which ranks 119 out of 384 in the Biotechnology & Medical Research industry. It highlights that the company's current P/E ratio is -0.66, significantly below its …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary

PharmaCyte Biotech, Inc. reported fiscal 2026 results in its 10-K, showing zero revenue and a net loss of ($23.21M), a significant decline from the prior year's net income. The company reported a diluted loss per share of ($2.77) for 2026. Key business highlights include …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

PharmaCyte Biotech Inc (PMCB) Cash Flow

This article provides a detailed historical cash flow statement for PharmaCyte Biotech Inc (PMCB), covering quarterly and annual data up to FY2026Q3. It includes operating, investing, and financing cash flows, along with related figures such as net income, changes in working capital, and beginning/ending …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

PharmaCyte Biotech Inc (PMCB) Institutional Confidence

PharmaCyte Biotech Inc (PMCB) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 132.81% quarter-over-quarter to 9.99%. While James Simons is listed as the largest institutional …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

PMCB|PharmaCyte Biotech Inc|Price:0.586|Chg%:-0.014

TradingKey provides a comprehensive stock analysis for PharmaCyte Biotech Inc (PMCB), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The analysis notes high institutional ownership but predicts a downward trend in the medium …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of PharmaCyte Biotech Inc (PMCB), highlighting major individual and institutional holders. Key shareholders include Joshua Silverman, Citadel Advisors LLC, and HRT Financial LP. The report also breaks down shareholder types and institutional holdings quarter by quarter, showing changes …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for PharmaCyte Biotech Inc (PMCB). It states that the company has not distributed any dividends over the past five years. The page also offers current market data including its stock price, market cap, …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB

This article provides a basic overview of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) on TradingView. It indicates that no trades occurred as the market was closed and highlights the availability of financial data, company information, and community features on the platform for PMCB. The content …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Market update Main company 🇺🇸 United States

PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN

This document is a Form 4 statement filed by PharmaCyte Biotech, detailing changes in beneficial ownership of securities for Director Jonathan Schechter. The filing indicates transactions related to his holdings within the company.

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity

PharmaCyte Biotech, Inc. Director Michael M. Abecassis filed an amended Form 4/A, which clarifies a previous insider transaction. The amendment states that an earlier reported grant of a stock option was made in error and has since been canceled, resulting in zero shares and …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

PharmaCyte Biotech (PMCB) cancels erroneous stock option grant

PharmaCyte Biotech (PMCB) director Robert Weinstein has corrected a stock option award previously granted on March 31, 2026. The initial grant, reported as a Stock Option (Right to Buy), was made in error and has now been officially cancelled. This amendment to the Form …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant

PharmaCyte Biotech director Jonathan Schechter filed an amended insider report (Form 4/A) to cancel a previously reported stock option grant dated March 31, 2026. This amendment clarifies that the initial grant was made in error and has been subsequently cancelled, resulting in zero outstanding …

PMCB main company
Sharemaestro market context Price below Trend Line 52 weeks -43.2% · Next-week setup negative 43.2% PMCB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context